MedTrace Logo

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

NCT05630989 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-05-05

No results posted yet for this study

Summary

This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).

Conditions

Interventions

OTHER

combination therapy with no MEKi

This cohort will receive combination therapy with no MEKi.

DRUG

combination therapy with MEKi-HCQ

This cohort will receive combination therapy with MEKi-HCQ.

DRUG

combination therapy with MEKi-EGFRi

This cohort will receive combination therapy with MEKi-EGFRi.

DRUG

combination therapy with MEKi.

This cohort will receive combination therapy with MEKi.

Sponsors & Collaborators

  • Mandana Kamgar, MD

    lead OTHER

Principal Investigators

  • Mandana Kamgar, MD, MPH · Medical College of Wisconsin

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-07
Primary Completion
2027-08-01
Completion
2027-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05630989 on ClinicalTrials.gov